Our Research Publications
Updated November 2023
Pagination
- Previous page
- Page 9
- Next page
Title Sort descending | Authors | Year | Journal | Link to Article | Intended Audience | Purpose |
---|---|---|---|---|---|---|
Characterization of SHP-1 protein tyrosine phosphatase transcripts, protein isoforms and phosphatase activity in epithelial cancer cells | Evren S, Wan S, Ma XZ, Fahim S, Mody N, Sakac D, Jin T, Branch DR | 2013 | Genomics | View Characterization of SHP-1 protein tyrosine phosphatase transcripts, protein isoforms and phosphatase activity in epithelial cancer cells | Researchers | Basic research |
Characterization of the growth dynamics and biofilm formation of Staphylococcus epidermidis strains isolated from contaminated platelet units | Ali H, Greco-Stewart VS, Jacobs MR, Yomtovian RA, Rood IG, de Korte D, Ramirez-Arcos S | 2014 | J Med Microbiol | View Characterization of the growth dynamics and biofilm formation of Staphylococcus epidermidis strains isolated from contaminated platelet units | Blood operators | Basic research |
Characterization of the growth modulatory activities of osteoblast conditioned media on cord blood progenitor cells | Abu-Khader A, Pasha R, Ward GCD, Boisjoli G, Pineault N | 2016 | Cytotechnology | View Characterization of the growth modulatory activities of osteoblast conditioned media on cord blood progenitor cells | Researchers | Basic research |
Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study | Chornenki NLJ, Siegal DM, Qamar K, Woolgar S, Rangarajan S, Karampatos S, Leong DP, Hillis CM | 2022 | Leuk Res | View Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study | Researchers | Clinical research |
Characterizing the ability of an ice recrystallization inhibitor to improve platelet cryopreservation | Waters L, Ben R, Acker JP, Padula MP, Marks DC, Johnson L | 2020 | Cryobiology | View Characterizing the ability of an ice recrystallization inhibitor to improve platelet cryopreservation | Researchers | New or improved product or process |
Chemoenzymatic Synthesis of a Type 2 Blood Group A Tetrasaccharide and Development of High-throughput Assays Enables a Platform for Screening Blood Group Antigen-cleaving Enzymes | Kwan DH, Ernst S, Kotzler MP, Withers SG | 2015 | Glycobiology | View Chemoenzymatic Synthesis of a Type 2 Blood Group A Tetrasaccharide and Development of High-throughput Assays Enables a Platform for Screening Blood Group Antigen-cleaving Enzymes | Researchers | Basic research |
Chemokines IP-10/CXCL10 and IL-8/CXCL8 are potential novel biomarkers of warm autoimmune hemolytic anemia | Branch DR, Leger RM, Sakac d, Yi Q, Duong T, Yeung RSM, Binnington B, Bloch EM | 2022 | Blood Adv | View Chemokines IP-10/CXCL10 and IL-8/CXCL8 are potential novel biomarkers of warm autoimmune hemolytic anemia | Researchers | Basic research |
Children under 10 years of age were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic in Canada: ?possible cohort effect following the 2009 influenza pandemic | Skowronski DM, Leir S, De Serres G, Murti M, Dickinson JA, Winter A-L, Olsha R, Croxen MA, Drews SJ, Charest H, Martineau C, Sabaiduc S, Bastien N, Li Y, Petric M, Jassem A, Krajden M, Gubbay JB | 2019 | Euro Surveill | View Children under 10 years of age were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic in Canada: ?possible cohort effect following the 2009 influenza pandemic | Health care providers | Clinical research |
Chloride and other electrolyte concentrations in commonly available 5% albumin products | Lai AT, Zeller MP, Millen T, Kavsak P, Szczeklik W, Elahie A, Alhazzani W, D'Aragon F, Jaeschke R, Lamontagne F, Karachi T, Cook D, Meade M, Rochwerg B | 2018 | Crit Care Med | View Chloride and other electrolyte concentrations in commonly available 5% albumin products | Researchers | Clinical research |
Chloride and other electrolyte concentrations in commonly available 5% albumin products | Lai AT, Zeller MP, Millen T, Kavsak P, Szczeklik W, Elahie A, Alhazzani W, D'Aragon F, Jaeschke R, Lamontagne F, Karachi T, Cook D, Meade M, Rochwerg B, on behalf of The Canadian Critical Care Trials Group | 2018 | Crit Care Med | View Chloride and other electrolyte concentrations in commonly available 5% albumin products | Health care providers | Clinical research |
Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis | Murphy AJ, Bijl N, Yvan-Charvet L, Welch CB, Bhagwat N, Reheman A, Wang Y, Shaw JA, Levine RL, Ni H, Tall AR, Wang N | 2013 | Nat Med | View Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis | Researchers | Basic research |
Circulaire d'information utilisation de composants sanguins humains: Cellules progénitrices hématopiétiques de sang de cordon omilical | Stewart T | 2022 | Blood.ca website | View Circulaire d'information utilisation de composants sanguins humains: Cellules progénitrices hématopiétiques de sang de cordon omilical | Health care providers | Benchmarking and standard setting |
Circulaire d'information utilisation de composants sanguins humains: Cellules progénitrices hématopoïétiques de sang de cordon ombilical | Jenkins C | 2020 | Blood.ca website | Health care providers | Benchmarking and standard setting | |
Circulaire d'information utilisation de composants sanguins humains: Cellules progénitrices hématopoïétiques de sang de cordon ombilical | Stewart T | 2021 | Blood.ca website | View Circulaire d'information utilisation de composants sanguins humains: Cellules progénitrices hématopoïétiques de sang de cordon ombilical | Health care providers | Benchmarking and standard setting |
Circulaire d'information utilisation de composants sanguins humains: Composants plasmatiques | Jenkins C | 2018 | Blood.ca website | View Circulaire d'information utilisation de composants sanguins humains: Composants plasmatiques | Health care providers | Benchmarking and standard setting |
Circulaire d'information utilisation de composants sanguins humains: Composants plasmatiques | Jenkins C | 2019 | Blood.ca website | View Circulaire d'information utilisation de composants sanguins humains: Composants plasmatiques | Health care providers | Benchmarking and standard setting |
Circulaire d'information utilisation de composants sanguins humains: Composants plasmatiques | Jenkins C | 2021 | Blood.ca website | Health care providers | Benchmarking and standard setting | |
Circulaire d'information utilisation de composants sanguins humains: Composants plasmatiques | Stewart T | 2022 | Blood.ca website | View Circulaire d'information utilisation de composants sanguins humains: Composants plasmatiques | Health care providers | Benchmarking and standard setting |
Circulaire d'information utilisation de composants sanguins humains: Composants plasmatiques | Stewart T | 2023 | Blood.ca website | View Circulaire d'information utilisation de composants sanguins humains: Composants plasmatiques | Health care providers | Benchmarking and standard setting |
Circulaire d'information utilisation de composants sanguins humains: Concentrés plaquettaires à pathogènes inactivés | Stewart T | 2022 | Blood.ca website | View Circulaire d'information utilisation de composants sanguins humains: Concentrés plaquettaires à pathogènes inactivés | Health care providers | Benchmarking and standard setting |
Circulaire d'information utilisation de composants sanguins humains: Culot globulaire partiellement déleucocyté (PD) | Jenkins C | 2021 | Blood.ca website | Health care providers | Benchmarking and standard setting | |
Circulaire d'information utilisation de composants sanguins humains: Plaquettes | Jenkins C | 2018 | Blood.ca website | View Circulaire d'information utilisation de composants sanguins humains: Plaquettes | Health care providers | Benchmarking and standard setting |
Circulaire d'information utilisation de composants sanguins humains: Plaquettes | Jenkins C | 2021 | Blood.ca website | Health care providers | Benchmarking and standard setting | |
Circulaire d'information utilisation de composants sanguins humains: Plaquettes | Stewart T | 2022 | Blood.ca website | View Circulaire d'information utilisation de composants sanguins humains: Plaquettes | Health care providers | Benchmarking and standard setting |
Circulaire d'information utilisation de composants sanguins humains: Plaquettes | Stewart T | 2022 | Blood.ca website | View Circulaire d'information utilisation de composants sanguins humains: Plaquettes | Health care providers | Benchmarking and standard setting |
Circulaire d'information utilisation de composants sanguins humains: Sang total | Stewart T | 2022 | Blood.ca website | View Circulaire d'information utilisation de composants sanguins humains: Sang total | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Hematopoietic Progenitor Cells (HPC) Cord Blood | Stewart T | 2021 | Blood.ca website | View Circular of information for the use of human blood components: Hematopoietic Progenitor Cells (HPC) Cord Blood | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Hematopoietic Progenitor Cells (HPC), Cord Blood | Jenkins C | 2015 | Blood.ca website | View Circular of information for the use of human blood components: Hematopoietic Progenitor Cells (HPC), Cord Blood | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Hematopoietic progenitor cells (HPC), cord blood | Jenkins C | 2020 | Blood.ca website | View Circular of information for the use of human blood components: Hematopoietic progenitor cells (HPC), cord blood | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Hematopoietic Progenitor Cells (HPC), Cord Blood | Jenkins C | 2021 | Blood.ca website | Health care providers | Benchmarking and standard setting | |
Circular of information for the use of human blood components: Hematopoietic Progenitor Cells (HPC), Cord Blood | Stewart T | 2022 | Blood.ca website | View Circular of information for the use of human blood components: Hematopoietic Progenitor Cells (HPC), Cord Blood | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Pathogen Reduced Platelet Concentrates | Stewart T | 2022 | Blood.ca website | View Circular of information for the use of human blood components: Pathogen Reduced Platelet Concentrates | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Plasma components | Jenkins C | 2018 | Blood.ca website | View Circular of information for the use of human blood components: Plasma components | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Plasma components | Jenkins C | 2018 | Blood.ca website | View Circular of information for the use of human blood components: Plasma components | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Plasma Components | Jenkins C | 2019 | Blood.ca website | View Circular of information for the use of human blood components: Plasma Components | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Plasma components | Jenkins C | 2021 | Blood.ca website | Health care providers | Benchmarking and standard setting | |
Circular of information for the use of human blood components: Plasma Components | Stewart T | 2022 | Blood.ca website | View Circular of information for the use of human blood components: Plasma Components | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Plasma Components | Stewart T | 2023 | Blood.ca website | View Circular of information for the use of human blood components: Plasma Components | Health care providers | Benchmarking and standard setting |
Circular of Information for the use of human blood components: Platelets | Jenkins C | 2017 | Blood.ca website | View Circular of Information for the use of human blood components: Platelets | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Platelets | Jenkins C | 2018 | Blood.ca website | View Circular of information for the use of human blood components: Platelets | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Platelets | Jenkins C | 2021 | Blood.ca website | Health care providers | Benchmarking and standard setting | |
Circular of information for the use of human blood components: Platelets | Stewart T | 2022 | Blood.ca website | View Circular of information for the use of human blood components: Platelets | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Platelets | Stewart T | 2022 | Blood.ca website | View Circular of information for the use of human blood components: Platelets | Health care providers | Benchmarking and standard setting |
Circular of Information for the use of human blood components: Red Blood Cells, Leukocytes Reduced (LR) | Jenkins C | 2017 | Blood.ca website | View Circular of Information for the use of human blood components: Red Blood Cells, Leukocytes Reduced (LR) | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Red blood cells, Leukocytes Reduced (LR) | Jenkins C | 2018 | Blood.ca website | View Circular of information for the use of human blood components: Red blood cells, Leukocytes Reduced (LR) | Health care providers | Benchmarking and standard setting |
Circular of information for the use of human blood components: Red blood cells, leukocytes reduced (LR) | Jenkins C | 2021 | Blood.ca website | Health care providers | Benchmarking and standard setting | |
Circular of information for the use of human blood components: Whole Blood | Stewart T | 2022 | Blood.ca website | View Circular of information for the use of human blood components: Whole Blood | Health care providers | Benchmarking and standard setting |
Circulare d'information utilisation de composants sanguins humains: Cellules progénitrices hématopoïétiques de sang de cordon ombilical | Jenkins C | 2020 | Blood.ca website | View Circulare d'information utilisation de composants sanguins humains: Cellules progénitrices hématopoïétiques de sang de cordon ombilical | Health care providers | Benchmarking and standard setting |
Circulare d'information utilisation de composants sanguins humains: Culot globulaire partiellement déleuccoyté (PD) | Jenkins C | 2018 | Blood.ca website | View Circulare d'information utilisation de composants sanguins humains: Culot globulaire partiellement déleuccoyté (PD) | Health care providers | Benchmarking and standard setting |
Circulatory Death Determination in Uncontrolled Organ Donors: A Panel Viewpoint | Bernat JL, Bleck TP, Blosser SA, Bratton SL, Capron AM, Cornell D, Devita MA, Fulda GJ, Glazier AK, Gries CJ, Mathur M, Nakagawa TA, Shemie SD | 2014 | Ann Emerg Med | View Circulatory Death Determination in Uncontrolled Organ Donors: A Panel Viewpoint | Health care providers | Other |